Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Association between serum copper levels and lungcancer risk: A meta-analysis. To evaluate the association between serum copper levels and lungcancer risk.We searched the electronic PubMed, WanFang, CNKI, and SinoMed databases to identify studies including information on serum copper levels and lungcancer. Standard mean differences and corresponding 95% confidence intervals were calculated using Stata 12.0 software. We performed a meta-analysis on the identified studies overall and according (...) to geographic location. We also evaluated heterogeneity among the studies and the occurrence of publication bias.Thirty-three articles including 3026 cases and 9439 controls were included in our study. The combined results showed that serum copper levels were higher in patients with lungcancer compared with controls without lungcancer, though the results showed high heterogeneity. In a subgroup analysis according to geographic location, significant associations between copper levels and lungcancer were
Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lungcancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. Synthetic thymic peptides (sTPs) are used with chemotherapy to treat non-small cell lungcancer (NSCLC). In this study, we have performed a systematic review and meta-analysis of published trials to confirm the clinical efficacy and safety of sTPs, and determine the optimal (...) , most with unclear bias risk. Combining sTPs with chemotherapy significantly increased the objective response rate [1.28, (1.13 to 1.45)], disease control rate [1.10, (1.01 to 1.18)], quality of life (QOL) [2.05, (1.62, 2.60)], and 1-year overall survival rate [1.43, (1.15 to 1.78)], with decreased risks of neutropenia, thrombocytopenia, and gastrointestinal reactions. Optimal conditions included treatment in combination with gemcitabine or navelbine and cisplatin, twice a week, with one 3
Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lungcancer. Whether video-assisted thoracoscopic surgery (VATS) segmentectomy and VATS lobectomy provide similar perioperative and oncological outcomes in stage I non-small cell lungcancer (NSCLC) is still controversial.Meta-analysis of 12 studies comparing outcomes after VATS lobectomy and VATS segmentectomy for stage I NSCLC. Data were analyzed by the RevMan
CT Characteristics of Non-Small Cell LungCancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis. OBJECTIVE. The purpose of this study was to perform a systematic review and meta-analysis regarding CT features of non-small cell lungcancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement. MATERIALS AND METHODS. The PubMed and Embase databases were searched up to February 20, 2019. Studies that evaluated CT features of NSCLC with and without ALK (...) prevalence of patients with ALK rearrangement was 17% (528/3113). Compared with NSCLC without ALK rearrangement, on CT images those with ALK rearrangement were more frequently solid (OR = 2.86), central in location (OR = 2.72), and 3 cm or smaller (OR = 0.57); had lower contrast-enhanced CT attenuation (MD = -4.79 HU); more frequently had N2 or N3 disease (OR = 5.63), lymphangitic carcinomatosis (OR = 3.46), pleural effusion (OR = 1.91), or pleural metastasis (OR = 1.81); and less frequently had lung
Video-assisted Thoracoscopic Surgery versus Thoracotomy for Non-Small Cell LungCancer: A Meta-Analysis. Patients undergoing surgery for non-small cell lungcancer (NSCLC) are often elderly and have co-morbidity conditions and decreased performance status. Compared with open thoracotomy, video-assisted thoracoscopic lobectomy is associated with fewer postoperative complications. Despite encouraging results for patients with NSCLC who underwent VATS, the procedure is still not widely accepted
Efficacy and Safety of Robot-assisted Thoracic Surgery (RATS) Compare with Video-assisted Thoracoscopic Surgery (VATS) for Lung Lobectomy in Patients with Non-small Cell LungCancer. In the past decade, many researchers focused on Robotic- Assisted Thoracoscopic Surgery (RATS), which has been introduced as an alternative minimally invasive approach, versus Video- Assisted Thoracoscopic Surgery (VATS) for lung lobectomy in patients with non-small cell lungcancer. However, the advantage of RVATS (...) compared to VATS is still under investigation. The results are unclear.The aim of this study is to compare the efficacy and safety of Robot-assisted Thoracic Surgery (RATS) lobectomy versus Video-assisted Thoracic Surgery (VATS) for lobectomy in patients with Non- Small Cell LungCancer (NSCLC).A systematic electronic search of online electronic databases: Pubmed, Embase, Cochrane library updated in June 2017. The meta-analysis was performed including the studies are designed as randomized or non
CHRNA5 rs16969968 polymorphism is associated with lungcancer risk: A meta-analysis. To evaluate the genetic association between rs16969968 and lungcancer risk by meta-analysis.We searched eligible studies from MEDLINE, Web of Science and EMBASE up to Dec, 2017.Association studies concerning rs16969968 and lungcancer risk were included. We assessed the association strength between this polymorphism and risk of lungcancer by calculating odds ratios (OR) and 95% confidence interval (95%CI (...) ).A total of 26 data sets comprising 30 772 lungcancers and 90 954 controls were included. rs16969968 was found to be associated with lungcancer risk in population of European ancestry in all models (A vs. G: OR = 1.30, 95%CI 1.27-1.33, P < 0.001; AA + GA vs. GG: OR = 1.38, 95%CI 1.33-1.43, P < 0.001; AA vs. GG + GA: OR = 1.45, 95%CI 1.38-1.53, P < 0.001), consistent with previous genome-wide association study (GWAS). However, no association was observed in Asians (A vs. G: OR = 1.19. 95%CI 0.95-1.49
Downregulation of hsa-microRNA-204-5p and identification of its potential regulatory network in non-small cell lungcancer: RT-qPCR, bioinformatic- and meta-analyses. Pulmonary malignantneoplasms have a high worldwide morbidity and mortality, so the study of these malignancies using microRNAs (miRNAs) has attracted great interest and enthusiasm. The aim of this study was to determine the clinical effect of hsa-microRNA-204-5p (miR-204-5p) and its underlying molecular mechanisms in non-small (...) cell lungcancer (NSCLC).Expression of miR-204-5p was investigated by real-time quantitative PCR (RT-qPCR). After data mining from public online repositories, several integrative assessment methods, including receiver operating characteristic (ROC) curves, hazard ratios (HR) with 95% confidence intervals (95% CI), and comprehensive meta-analyses, were conducted to explore the expression and clinical utility of miR-204-5p. The potential objects regulated and controlled by miR-204-5p in the course
Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lungcancer and malignant pleural effusion? Debulking surgery and hyperthermic intrathoracic chemotherapy (HITHOC) has been successfully used in the treatment of thoracic tumours. Few authors report on the feasibility of its use in patients with lungcancer and malignant pleural effusion. The aim of this study was to evaluate the efficacy and results of debulking surgery (...) and HITHOC in the treatment of selected patients with nonsmall cell lungcancer (NSCLC) and malignant pleural effusion.A systematic review was conducted in MEDLINE in accordance with PRISMA guidelines. The word search included: "hyperthermic intrathoracic chemotherapy and/or HITHOC or hyperthermic intrapleural". Inclusion criteria were only those studies reporting a sufficient amount of data on HITHOC and surgery for lungcancer. Single case reports and review articles were excluded.20 articles were
Is carrot consumption associated with a decreased risk of lungcancer? A meta-analysis of observational studies. 32070440 2020 03 03 1475-2662 123 7 2020 Apr 14 The British journal of nutrition Br. J. Nutr. Is carrot consumption associated with a decreased risk of lungcancer? A meta-analysis of observational studies. 840 10.1017/S0007114520000343 Xu Hongbin H Jiang Heng H Yang Wei W Song Fujian F Yan Shijiao S Wang Chao C Fu Wenning W Li Hui H Lyu Chuanzhu C Gan Yong Y Lu Zuxun Z eng Journal
Efficacy and toxicities of combination maintenance therapy in the treatment of advanced non-small-cell lungcancer: an up-to-date meta-analysis. Background: Single agent maintenance therapy has been approved for the treatment of advanced non-small-cell lungcancer (NSCLC) due to its potential survival benefits, but whether combined maintenance therapy would improve the survival of advanced NSCLC remains undetermined.Methods: Relevant trials were identified by searching electronic databases
Clinical efficacy and safety of aidi injection combination with vinorelbine and cisplatin for advanced non-small-cell lungcarcinoma: A systematic review and meta-analysis of 54 randomized controlled trials. The Aidi injection contains multiple active ingredients, including astragaloside (Re, Rb1, and Rg1), ginsenoside, cantharidin, elentheroside E, and syringin, and it is administered with vinorelbine and cisplatin (NP) to treat non-small-cell lungcarcinoma (NSCLC). In this study, we (...) the Grading of Recommendations Assessment, Development and Evaluation approach. We included 54 trials containing 4,053 patients for analysis. Combining the Aidi injection with NP significantly increased the objective response rate (odds ratio [OR], 1.32; confidence interval [CI], 1.23, 1.42), disease control rate (OR, 1.14; CI, 1.11, 1.18), and quality of life (OR, 1.80; CI, 1.61, 1.98), with decreased risks of myelosuppression, neutropenia, thrombocytopenia, anemia, gastrointestinal reaction, and liver
Occupational exposure to formaldehyde and risk of lungcancer: A systematic review and meta-analysis. Formaldehyde exposure is associated with nasopharyngeal cancer and leukemia. Previously-described links between formaldehyde exposure and lungcancer have been weak and inconsistent. We performed a systematic review and meta-analysis to evaluate quantitatively the association between formaldehyde exposure and lung cancer.We searched for articles on occupational formaldehyde exposure and lung (...) cancer in PubMed, EMBASE, Web of Science, and CINAHL databases. In total, 32 articles were selected and 31 studies were included in a meta-analysis. Subgroup analyses and quality assessments were also performed.The risk of lungcancer among workers exposed to formaldehyde was not significantly increased, with an overall pooled risk estimate of 1.04 (95% confidence interval [CI], 0.97-1.12). The pooled risk estimate of lungcancer was increased when higher exposure studies were considered (1.19; 95
: about 60% of NSCLCs are adenocarcinoma. Former or current smoking is often a causal factor in all forms of lungcancer. However, nonsmokers with lungcancer frequently have adenocarcinoma. This type of cancer is usually found on the outer parts of the lung. People with adenocarcinoma tend to have better survival than people with other types of lungcancer • Squamous cell (epidermoid) carcinoma: 25% to 30% of all NSCLCs are squamous cell carcinomas. Squamous cells are flat cells that line the inside (...) • Other subtypes: Less common NSCLC subtypes include adenosquamous carcinoma and sarcomatoid carcinoma The progression of cancer is divided into four stages; a higher number signifies more extensive disease. In stage 1, the cancer is confined to the original site within the lung and there is no sign of spread to lymph nodes (N0) or elsewhere (M0). In stage 2, the cancer has spread to lymph nodes within the lung (N1). In stage 3, the cancer has spread to lymph nodes in the middle of the chest
(Lorviqua ® ) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC) whose disease has progressed after: ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI In the relevant subgroup of a non-comparative (...) Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lungcancer (NSCLC) whose disease has progressed after: 1 ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI Dosing Information The recommended dose is 100mg lorlatinib taken orally once daily. Treatment with lorlatinib
The Effect of Diabetes Mellitus on Prognosis of Patients with Non-Small-Cell LungCancer: A Systematic Review and Meta-Analysis. To quantitatively evaluate the effect of preexisting diabetes mellitus (DM) on the outcomes of patients with non-small-cell lungcancer (NSCLC).Observational studies comparing the prognosis of NSCLC patients with and without diabetes were identified from PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials (CENTRAL). We searched for studies
Effect of lidocaine cream analgesia for chest drain tube removal after video-assisted thoracoscopic surgery for lungcancer: a randomized clinical trial Pain management makes an important contribution to good respiratory care and early recovery after thoracic surgery. Although the development of video-assisted thoracoscopic surgery (VATS) has led to improved patient outcomes, chest tube removal could be distressful experience for many patients. The aim of this trial was to test whether (...) the addition of lidocaine cream would have a signiﬁcant impact on the pain treatment during chest tube removal from patients who had undergone VATS for lung cancer.This clinical trial was a double-blind randomized study. Forty patients with histologically confirmed lungcancer amenable to lobectomy/segmentectomy were enrolled. All patients had standard perioperative care. Patients were randomly assigned to receive either epidural anesthesia plus placebo cream (placebo, Group P) or epidural anesthesia plus
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell LungCancer RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lungcancer (NSCLC).The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the other, with a primary end point (...) survival (PFS) rates were 32.1% and 23% and 18.3% and 13% (P = .055), respectively. Factors associated with improved OS on multivariable analysis were standard radiation dose, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart V5. The use of cetuximab conferred no survival benefit at the expense of increased toxicity. The prior signal of benefit in patients with higher H scores was no longer apparent. The progression rate within 1 month of treatment
LungCancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non-small-cell lungcancer (NSCLC) and SCLC.ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care, and advocacy experts to conduct a literature (...) for this guideline.Patients should undergo surveillance imaging for recurrence every 6 months for 2 years and then annually for detection of new primary lungcancers. Chest computed tomography imaging is the optimal imaging modality for surveillance. Fluorodeoxyglucose positron emission tomography/computed tomography imaging should not be used as a surveillance tool. Surveillance imaging may not be offered to patients who are clinically unsuitable for or unwilling to accept further treatment. Age should not preclude
Prognostic value of pre-treatment red blood cell distribution width in lungcancer: a meta-analysis. Objective: In recent years, increasing studies found that pre-treatment red blood cell distribution width (RDW) could predict clinical outcomes in various cancers. However, the prognostic value of pre-treatment RDW in lungcancer was inconsistent. Therefore, we performed a meta-analysis to determine prognostic value of pre-treatment RDW in lung cancer.Methods: We performed a search in PubMed (...) , The Cochrane Library, EMBASE (via OVID), Web of Science, CNKI, Wanfang, VIP, SinoMed databases, then we identified all records up to February 15, 2019. Outcomes of interest were overall survival (OS) and disease-free survival (DFS). Hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were calculated to assess the relevance of pre-treatment RDW to OS in lung cancer.Results: We included ten articles in total. Pooled results revealed that elevated pre-treatment RDW was significantly